
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Alan L. Ho discloses the following relationships and financial interests:
-
Affyimmune Therapeutics, Inc.
Provision of Services -
American Society for Radiation Oncology
Provision of Services -
Ayala Pharmaceuticals, Inc
Provision of Services -
Cellestia Biotech AG
Provision of Services (uncompensated) -
Chemotherapy Foundation Symposium
Provision of Services -
CureVac
Provision of Services -
Eisai
Provision of Services -
Elevar Therapeutics
Provision of Services -
Emory University
Provision of Services -
Exelixis
Provision of Services -
InxMed (Hong Kong) Limited
Provision of Services -
KLUS Pharma, Inc
Provision of Services (uncompensated)
-
Kura Oncology
Provision of Services -
Leidos Biomedical Research, Inc.
Provision of Services -
Massachusetts General Hospital
Provision of Services -
McGivney Global Advisors
Provision of Services -
Merck & Co Inc.
Provision of Services (uncompensated) -
National Institutes of Health (NIH)
Provision of Services -
New York Head & Neck Society
Provision of Services -
New York University (NYU)
Provision of Services -
Physicians' Education Resource
Provision of Services -
Prelude Therapeutics
Provision of Services -
Rgenta Therapeutics Inc.
Ownership / Equity Interests; Provision of Services -
University of Pittsburgh
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
View all disclosures